Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038990 | 0.87 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11MEN1 | |
| SCHEMBL7030772 | 0.85 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11MEN1 | |
| SCHEMBL7033485 | 0.84 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL7512880 | 0.81 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7033526 | 0.80 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL7039292 | 0.79 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL1907099 | 0.79 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MEN1 | |
| SCHEMBL7036540 | 0.79 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11MEN1 | |
| SCHEMBL7040214 | 0.78 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11MEN1 | |
| SCHEMBL7035891 | 0.78 | MAPK13 (0.67) | MAPK14MAPK13MAPK12MAPK11POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289958-A2 | BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) | Leo Pharma A/S (DK) | 2003-03-12 | — | — | EP | claimed |
| US-6432962-B2 | Benzophenones as inhibitors of IL-1β and TNF-α | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-08-13 | — | — | US | claimed |
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-07 | — | — | US | claimed |
| WO-2001090074-A2 | BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | LEO PHARMA A/S (DK) | 2001-11-29 | — | — | WO | claimed |
| EP-1289958-A2 | BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) | Leo Pharma A/S (DK) | 2003-03-12 | — | — | EP | disclosed |
| US-6432962-B2 | Benzophenones as inhibitors of IL-1β and TNF-α | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-08-13 | — | — | US | disclosed |
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| WO-2001090074-A2 | BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | LEO PHARMA A/S (DK) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | IL1B, IL1A, NFKBIA | MAPK14 625/4885MAPK13 1908/4885MAPK12 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.